Current evidence and future research needs for FeNO measurement in respiratory diseases
Leif Bjermer(Lund University), Omar S. Usmani(Guy's and St Thomas' NHS Foundation Trust), David Price(Optimum Therapeutics (United States)), Giorgio Piacentini(University of Verona), Mike Thomas(University of Southampton), Ian Pavord(Oxford BioMedica (United Kingdom)), Kjell Alving(Uppsala University), J. Sastre(Centro de Investigación Biomédica en Red de Enfermedades Respiratorias), Nicolás Roche(Hôpital Cochin), H Magnussen(LungenClinic Grosshansdorf), Zuzana Diamant(Lund University)
Cited by 183
Related Papers
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
|Science|2020|3.2k
Effectiveness and Safety of Bronchial Thermoplasty in the Treatment of Severe Asthma: A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Trial
|American Journal of Respiratory and Critical Care Medicine|2009|686
Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD
|New England Journal of Medicine|2014|621
Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study
|The Lancet Respiratory Medicine|2015|584
MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
|Journal of Allergy and Clinical Immunology|2010|578